Devonian Health Group, Inc. (TSE:GSD) has released an update.
Devonian Health Group Inc. has reported an impressive 1,162% increase in third-quarter revenue, despite a minimal per share net loss, signaling robust financial growth primarily due to its subsidiary Altius’s success with the GERD treatment, DEXLANSOPRAZOLE. Alongside these financial gains, the company is advancing its phase II/III clinical study for Thykamine in treating pediatric atopic dermatitis and has strengthened its leadership team to enhance research and production capabilities.
For further insights into TSE:GSD stock, check out TipRanks’ Stock Analysis page.
